By Plenary Sessions: Irja Lutsar

The speaker demonstrates profound expertise in pharmaceutical regulatory affairs, clinical trial methodology, and specific treatment modalities (such as CAR-T cell therapy). They reference specific legal sections (e.g., Section 167 of the Medicines Act) and employ technical terminology, underscoring the requirements for evaluating the quality, efficacy, and safety of medicinal products. The arguments are substantiated with concrete examples, including the Bioblock studies and the recent contamination incident involving Avastin in a hospital pharmacy.

The speaker demonstrates knowledge of the synthetic cannabinoid supply chain, highlighting their origin in China and subsequent distribution via postal packages ordered online. Furthermore, China's legal stance, which permits the production of these substances within its borders, is also noted, suggesting a focus on the international legal environment.

The speaker demonstrates knowledge on the topic of public health and vaccination, referencing a response written by experts from the State Agency of Medicines (Ravimiamet) and its subsequent publication in Delfi. They rely on institutional expertise to support their claims, and emphasize that the experts' response is understandable even without a background in biology or medicine.

The expert analysis focused on the internal rules of the Riigikogu and the working procedures of its committees, highlighting systematic non-attendance. He relies on personal observations to describe behavioral patterns, noting the early departure of a specific group.

The speaker demonstrates expertise regarding children's rights protocols and is interested in the technical details of the legislation, such as the definition of a child and the liability associated with filing a complaint. He/She stresses the necessity of focusing the discussion on the specific protocol, rather than jumping between topics (e.g., care homes or family benefits).